FibriCheck
Diagnostic TestDigital health application
NCT Number: NCT03509493
FibriCheck is a Conformité Européenne (CE)-approved (class IIa) medically diagnostic application that allows for heart rhythm registrations based on an optical signal captured via the smartphone camera. FibriCheck is only available on prescription causing the physician to stay in the 'driving seat' and the application distribution to be traced.
By using FibriCheck, a medically validated smartphone application, daily rhythm measurements can be performed using only the smartphone of the patient. This allows for the heart rhythm to be registered and monitored in a home environment and the data to be automatically sent to the physician. This enables the implementation of FibriCheck in two types of scenarios:
* Scenario 1: the follow-up of patients with high risk parameters for AF development for primary and secondary prevention, whereby detection of AF will result in therapeutic intervention * Scenario 2: the realisation of monitoring of the heart rhythm of patients post intervention in a home environment
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ziekenhuis Oost Limburg, Genk, Limburg, Belgium
Atrial fibrillation (AF) is the most common heart rhythm disorder affecting 50 million people in Europe and the U.S. It is associated with an increasing mortality and risk for transient cerebrovascular incidents and dementia. De novo AF is in most cases asymptomatic and paroxysmal, causing the diagnosis to be made either by chance or in response to an incident. This drastically impacts the quality of life of the patient and is accompanied with a high socio-economic cost. Guidelines indicate that anticoagulation in patients diagnosed with AF is a cost-effective solution for the prevention of strokes.
In addition, depending on the target group, patients identified with AF can receive therapy in order to control the heart rhythm. These procedures (cardioversion and ablation) often result in follow-up consultations that can be avoided if the heart rhythm can be monitored remotely.
By using FibriCheck, a medically validated smartphone application, daily rhythm measurements can be performed using only the smartphone of the patient. This allows for the heart rhythm to be registered and monitored in a home environment and the data to be automatically sent to the physician. This enables the implementation of FibriCheck in two types of scenarios:
The follow-up of patients is still driven by the treating physician(s). The objective is to implement a correct and successful process management allowing a smooth implementation of "an application on prescription".
Short- and long-term benefits the project wants to prove:
Short-term:
Long-term: a successful detection of AF in a home environment can:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Group 1: Patients without structural heart disease
Group 2: Patients with structural heart disease
Group 3: Patients with high risk parameters for AF development
Group 4: Patients post-cryptogenic stroke or TIA
Group 5: Patients post-cardioversion therapy
Group 6: Patients post-ablation therapy
Exclusion criteria
Digital health application
Time frame: 31 December 2017
Time frame: 31 December 2017
Qompium NV
Industry
Detection of the Common Arrhythmia Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial DetailsNCT05993897
Arrhythmias, Cardiac, Atrial Fibrillation
Aswān, Aswan Governorate, Egypt
View Trial DetailsNCT05357690
Arrhythmias, Cardiac, Atrial Fibrillation
Rochester, Minnesota, United States
View Trial DetailsNCT05164718
Arrhythmias, Cardiac, Atrial Fibrillation
Drammen, Norway
View Trial Details